Page 332 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.14. Treatment characteristics—changes in treatment patterns over time (continued)
Author Database Treatment 1980- 1985-89 1990-94 1995- 2000-04 2005- Statistical Notes
Year 84 99 10 analysis
PMID
“Definitive 74.1% 69.3% NR Proportions
therapy” (BT or adjusted for
EBRT or RP) 25.9% 30.7% age, marital
No “definitive (1992-94) (2000-02) status,
therapy” physician
[Black] visits,
geographic
region, cancer
stage and
grade and
comorbid
conditions
4
Cooperberg CaPSURE BT 3.7% 5.7% 18.4% NR PSA≤10.0
2003 EBRT 15.3% 10.0% 6.8% ng/ml,
14610406 RP 62.6% 54.6% 51.9% Gleason
PADT 4.6% 16.7% 14.2% score≤6, and
WW 13.7% 12.9% 8.3% clinical stage
[Low risk] (1989-92) (1996- (1999- T1 or T2a;
98) 2001) excluded
patients
undergoing
cryotherapy
BT 3.3% 5.6% 11.8% NR PSA≤10.1-
EBRT 22.5% 18.0% 19.1% 20.0 ng/ml,
RP 55.3% 49.4% 45.0% Gleason
PADT 8.9% 21.3% 19.7% score=7, or
WW 10.0% 5.6% 4.5% clinical stage
[Intermediate (1989-92) (1996- (1999- T2a; excluded
risk] 98) 2001) patients
undergoing
cryotherapy

C-84